Founded in 1997, Ergomed is a complete, global Phase I-IV clinical development and trial management service partner with leading expertise in developing drugs in rare diseases and oncology. Pioneers in rare disease drug development since 1998, Ergomed orphan experts embody a family & patient-centric approach to recruitment and retention with access to global patients in vital geographical areas. To further strengthen Ergomed CRO's strong operational footprint and expertise in rare diseases and oncology, Ergomed invested in a strategic US acquisition of MedSource CRO that has been fully integrated in early 2021. For more information about Ergomed, please visit:

Get Involved At World Orphan Drug Congress USA


To Sponsor Or Exhibit


Justin Franks
t/ +1 914 819 3506




To Speak


Claire Murphy
t/ +1 646 619 1784




Marketing & Press Opportunities


Taylor Post
t/ +1 646 619 1785